Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of “Moderate Buy” by Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received an average rating of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $10.00.

A number of research firms have recently commented on AMRX. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective on the stock in a report on Friday, September 6th. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Truist Financial boosted their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. Finally, Piper Sandler raised their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the transaction, the senior vice president now owns 13,665 shares in the company, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 26.56% of the company’s stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMRX. Franklin Resources Inc. lifted its position in shares of Amneal Pharmaceuticals by 4.9% during the 3rd quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock valued at $778,000 after acquiring an additional 4,178 shares during the last quarter. Geode Capital Management LLC increased its stake in Amneal Pharmaceuticals by 11.1% in the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock worth $31,511,000 after purchasing an additional 378,136 shares in the last quarter. Barclays PLC increased its stake in Amneal Pharmaceuticals by 134.1% in the 3rd quarter. Barclays PLC now owns 296,384 shares of the company’s stock worth $2,466,000 after purchasing an additional 169,756 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Amneal Pharmaceuticals during the 3rd quarter worth about $311,000. Finally, Wellington Management Group LLP purchased a new stake in Amneal Pharmaceuticals during the third quarter valued at about $687,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Up 0.4 %

Shares of AMRX opened at $7.78 on Friday. Amneal Pharmaceuticals has a twelve month low of $5.01 and a twelve month high of $9.48. The firm has a market capitalization of $2.41 billion, a P/E ratio of -11.44 and a beta of 1.12. The stock’s fifty day simple moving average is $8.42 and its 200 day simple moving average is $7.94.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.